Karyopharm Expanded Access Program for Selinexor

• Conditions: Multiple Myeloma; Diffuse Large B-Cell Lymphoma (DLBCL); Sarcoma; Neuroglioblastoma; Peripheral T-cell Lymphoma; Endometrial Cancer; Myelofibrosis; Other

• Registration Number: NCT07215832
• Lead Sponsor: Karyopharm Therapeutics Inc

Brief Summary

KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is commercially available in the country. Patients who do not qualify for an ongoing clinical trial but who might benefit from the investigational medicine may be eligible, provided they have exhausted all other available treatment options. Investigational medicines are provided to patients only through treating physicians who obtain the relevant approval on behalf of their patient from the relevant regulatory agency and follow all applicable safety-reporting regulations of the respective country.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-09
• Study First Submitted: 2025-09-30
• Study First Submitted QC: 2025-10-10
• Last Update Submitted: 2025-10-10
• Study First Posted: 2025-10-14
• Last Update Posted: 2025-10-14

Recruitment & Eligibility

• Status: AVAILABLE
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

-

Exclusion Criteria

-

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified